Novosti
Khirurgii
This journal is
indexed in Scopus









Year 2022 Vol. 30 No 1

TRAUMATOLOGY AND ORTHOPEDICS

DOI: https://dx.doi.org/10.18484/2305-0047.2022.1.61   |  

.E. MURZICH 1, .. SOKOLOVSKY 1, .L. EISMONT 1, YA.I. ISAYKINA 2

SURGICAL TREATMENT OF FEMORAL HEAD NECROSIS WITH PRE-DIFFERENTIATED MESENCHYMAL STEM CELLS

Republican Scientific and Practical Centre for Traumatology and Orthopedics1, Minsk,
Belarusian Research Center for Pediatric Oncology and Hematology 2, Borovliany, Minsk Region,
The Republic of Belarus

Objective. To study the results of pre-differentiated MSCs application in the treatment of femoral head necrosis in young patients.
Methods. The developed high-tech approach included: exfusion of 50-70 ml of patients bone marrow 4 weeks prior to implantation; osteogenic differentiation and obtaining a biomedical cell product; surgical decompression and introduction of pre-differentiated MSCs in fibrin gel; postoperative rehabilitation. Surgeries were performed in 25 patients at stages I and II according to the ARCO classification. The average age of patients is 34 [29; 45], men 20 (80%), women 5 (20%). The assessment scale is a visual analogue scale (VAS), Harris scale, radiography, MRI.
Results. Observation period was 41 [19; 59] month. Average Harris score before surgery was 76 [68.8; 79] points, after treatment 90 [78.9; 92] points. In 15 (60%) cases an excellent results were obtained, in 5 (20%) good, in 3 (12%) satisfactory, in 2 (8%) unsatisfactory (collapse progression). The level of pain syndrome was reduced from 40 [30; 50] to 10 [5; 25] points. There were no complications. Preservation of the femoral head sphericity and the width of the joint space, relief of bone marrow edema, reduction of the necrosis zone size and synovitis according to MRI data were found in 92% of cases.
Conclusion. The treatment method of femoral head necrosis with the use of pre-differentiated MSCs in the absence of infectious triggers in the lesion focus made it possible to preserve 95 % of cultured cells in the cell product composition and to introduce it minimally invasively, avoiding the need for bone graft collection. The introduction of the cellular technologies in practice made it possible to obtain positive treatment results in 92% of cases due to an improvement clinical condition by the Harris scale and reduce of pain syndrome compared to the initial state; it did not lead to infectious, allergic or other complications within the 41 [19; 59] month follow-up.

Keywords: femoral head, necrosis, mesenchymal stem cells, surgical decompression, fibrin gel
p. 61-73 of the original issue
References
  1. Hernigou P, Trousselier M, Roubineau F, Bouthors C, Chevallier N, Rouard H, Flouzat-Lachaniette CH. Stem cell therapy for the treatment of hip osteonecrosis: a 30-year review of progress. Clin Orthop Surg. 2016 Mar;8(1):1-8. doi: 10.4055/cios.2016.8.1.1
  2. Niyazov RR, Dranicyna MA, Yasnyi IE, Gavrishina EV, Vasilev AN.Regulation of the reserch and development of cellular drugs: the experience of the European Union and the United States. Geny i kletki. 2020;15(1):78-87. doi: 10.23868/202003011 (In Russ)
  3. Potapnev MP, Kravchuk ZI, Filanyuk VA. Cell technology in medical practice of healthcare organization in Belarus Republic. Zdravoohranenie. 2020;(11):50-60. https://elibrary.ru/item.asp?id=44503429 (In Russ.)
  4. Hernigou P, Manicom O, Poignard A, Nogier A, Filippini P, De Abreu L. Core decompression with marrow stem cells. Oper Tech Orthop. 2004 Apr;14(2):68-74. doi: 10.1053/j.oto.2004.03.001
  5. Yan Z, Hang D, Guo C, Chen Z. Fate of mesenchymal stem cells transplanted to osteonecrosis of femoral head. J Orthop Res. 2009 Apr;27(4):442-46. doi: 10.1002/jor.20759
  6. Zhernasechanka H, Isaikina Ya, Mikhaleuskaya T. The choice of scaffold and conditions for mesenchymal stem cells differentiation for the bone repair Nauka i Innovacii. 2019;(5):58-61. doi: 10.29235/1818-9857-2019-5-58-61 (In Russ.)
  7. Gardeniers JWM. ARCO Committee on terminology and staging. Report on the committee meeting at Santiago de Compostella. ARCO News Lett. 1993;5:79-82.
  8. McCormack HM, Horne DJ, Sheather S. Clinical applications of visual analogue scales: a critical review. Psychol Med. 1988 Nov;18(4):1007-19. doi: 10.1017/s0033291700009934
  9. Harris WH. Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment by mold arthroplasty. An end-result study using a new method of result evaluation. J Bone Joint Surg Am. 1969 Jun;51(4):737-55.
  10. Hernigou P, Beaujean F, Lambotte JC. Decrease in the mesenchymal stem-cell pool in the proximal femur in corticosteroid-induced osteonecrosis. J Bone Joint Surg Br. 1999 Mar;81(2):349-55. doi: 10.1302/0301-620x.81b2.8818
  11. Klingemann H, Matzilevich D, Marchand J. Mesenchymal Stem Cells - Sources and Clinical Applications. Transfus Med Hemother. 2008;35(4):272-277. doi: 10.1159/000142333
  12. Murzich AE, Pashkevich LA, Zhernasechanka HA. Experimental justification of the method of mesenchymal stem cell autotransplantation for regeneration of the femoral head bone tissue. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2020;17(1):7-19. doi: 10.29235/1814-6023-2020-17-1-7-19 (In Russ.)
  13. Mao Q, Jin H, Liao F, Xiao L, Chen D, Tong P. The efficacy of targeted intraarterial delivery of concentrated autologous bone marrow containing mononuclear cells in the treatment of osteonecrosis of the femoral head: a five year follow-up study. Bone. 2013 Dec;57(2):509-16. doi: 10.1016/j.bone.2013.08.022
  14. Homma Y, Kaneko K, Hernigou P. Supercharging allografts with mesenchymal stem cells in the operating room during hip revision. Int Orthop. 2014 Oct;38(10):2033-44. doi: 10.1007/s00264-013-2221-x
  15. Tabatabaee RM, Saberi S, Parvizi J, Mortazavi SM, Farzan M. Combining concentrated autologous bone marrow stem cells injection with core decompression improves outcome for patients with early-stage osteonecrosis of the femoral head: a comparative study. J Arthroplasty. 2015 Sep;30(9 Suppl):11-15. doi: 10.1016/j.arth.2015.06.022
Address for correspondence:
220024, Republic of Belarus,
Minsk, Kizhevatov Str., 60/4,
Republican Scientific and Practical Centre
for Traumatology and Orthopedics
tel. +375 17 212 32 88.
e-mail: mae77@list.ru,
Murzich Alyaksandr E.
Information about the authors:
Murzich Alyaksandr E., PhD, Deputy Director for Science, Republican Scientific and Practical Centre for Traumatology and Orthopedics, Minsk, Republic of Belarus.
https://orcid.org/0000-0003-1625-7321
Sakalouski Aleh A., MD, Professor, Head of Children and Adolescents Trauma and Orthopedic Laboratory, Republican Scientific and Practical Centre for Traumatology and Orthopedics, Minsk, Republic of Belarus.
https://orcid.org/0000-0001-8749-3802
Eismont Oleg L., MD, Associate Professor, Head of the Joint Pathology and Sports Injury Laboratory, Republican Scientific and Practical Centre for Traumatology and Orthopedics, Minsk, Republic of Belarus.
https://orcid.org/0000-0002-1002-4132
IsaykinaYanina I., PhD (Biol), Head of the Laboratory of Cell Biotechnology and Cytotherapy, Belarusian Research Center for Pediatric Oncology and Hematology, Borovliany, Minsk Region, Republic of Belarus.
Contacts | ©Vitebsk State Medical University, 2007